Accelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017
Feb 15, 2018
Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for Q4 of $2.1 million, doubling revenue for the year, and signed agreements for 337 instruments. Contracts for customer evaluations covered 259 instruments while revenue placements totaled 78 across the U.S., European, and Middle East regions.
Net sales were $4.2 million for the year compared to $246,000 for the prior year, 2016. The increase was driven by sales of the company’s solution for sepsis intervention and antimicrobial stewardship, the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit. The U.S. Food and Drug Administration (FDA) reviewed and permitted marketing of the system and kit in late February 2017.
- Accelerate Diagnostics Receives New Innovative Technology Contract from Vizient for the Accelerate Pheno™ System
Aug 07, 2018